More Access and Evidence Articles

Access and Evidence

The Naked Truth About Outcomes-Based Pricing

Ross Davies, (May 22, 2018)

Hype around outcomes-based contracts has been doing the rounds for some time now, but is pharma delivering the goods?
Access and Evidence

Japan’s Perilous New Pricing Policy

Ross Davies, (Apr 13, 2018)

The introduction of a new drug pricing reform in Japan has pharma up in arms. Are their fears justified?
Access and Evidence

Digital Health Tools Are No Fad

Adam Chapman, (Mar 14, 2018)

Data generating devices may seem gimmicky, but they are poised to transform healthcare
Access and Evidence

Overcoming The Access Hurdle

Adam Chapman, (Mar 6, 2018)

If pharma is to keep whizzing ahead, it needs to rethink its approach to market access
Access and Evidence

Could EHRs Boost Clinical Trial Recruitment?

Ross Davies, (Mar 6, 2018)

Patient recruitment for clinical trials is commonly accepted to be a herculean task. A new platform could make the process a lot quicker and easier – and, crucially, not at the expense of data privacy
Access and Evidence

Raising The Curtain On Real-World Evidence

Danielle Barron, (Feb 13, 2018)

RWE continues to animate expectations far and wide, but its success calls for level-headed pragmatism
Access and Evidence

Bridging The Evidence Gap

Danielle Barron, (Jan 15, 2018)

AstraZeneca's Head of Real World Evidence shares the story behind AZ's seminal RWE study and casts his projections on the future
Access and Evidence

Out With The OId, In With The New

Danielle Barron, (Jan 12, 2018)

Pharma must seek alternative pricing models if it is to become a greater dynamic force
Access and Evidence

It's Not You, It's Me

Danielle Barron, (Jan 8, 2018)

Despite its ups and downs, the relationship between pharma and payers is stronger than ever
Access and Evidence

The 5 conditions you need to deploy blockchain technology

Andy Robertson, (Jan 6, 2018)

Richie Etwaru, Chief Digital Officer at IQVIA explaining the 5 conditions you need in order to deploy blockchain.